Scholarlink

Background <p>Colorectal cancer (CRC) is a prevalent cancer. Heart failure (HF) is a well-recognized adverse reaction to CRC drugs.</p> Methods <p>This study interrogated the FDA Adverse Event Reporting System (FAERS) database from to comprehensively investigate the risk of HF associated with CRC drugs.</p> Results <p>The annual number of reports peaked in 2017 and has shown a consistent upward trend in the most recent period. The physicians constituted the most substantial group. Male patients contributed the most reports. The 65 to 85 age group constituted the majority of the reports. It is notable that the United States was the largest contributor of reports. The majority of HF reports occurred within 0 to 30&#xa0;days after drug administration. These reports were frequently associated with serious outcomes. There were 20 drugs that met the threshold of not less than 3 reports, including bevacizumab, oxaliplatin, fluorouracil, capecitabine, and cetuximab. The Reporting Odds Ratio (ROR) method, the Proportional Reporting Ratio (PRR) method, the Bayesian Confidence Propagation Neural Network (BCPNN) method, and the Multi-item Gamma Poisson Shrinker (MGPS) method were utilized. Fluorouracil, aflibercept, ramucirumab, atezolizumab, trametinib, and ipilimumab met the criteria of more than 3 reports and a positive ROR signal. A strong association between HF risk and the utilization of aflibercept or ramucirumab in CRC was found.</p> Conclusion <p>The study offers the first real-world pharmacovigilance analysis of HF risks associated with CRC drugs using the FAERS database. It contributed critical evidence to inform the safe clinical use of CRC drugs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The association between colorectal cancer drugs and heart failure: a real-world pharmacovigilance study of the FAERS database

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月14日

查看全文
  • Shuang Chen,
  • Keyun Lin,
  • Shiying Huang,
  • Mei Jiang

摘要

Background

Colorectal cancer (CRC) is a prevalent cancer. Heart failure (HF) is a well-recognized adverse reaction to CRC drugs.

Methods

This study interrogated the FDA Adverse Event Reporting System (FAERS) database from to comprehensively investigate the risk of HF associated with CRC drugs.

Results

The annual number of reports peaked in 2017 and has shown a consistent upward trend in the most recent period. The physicians constituted the most substantial group. Male patients contributed the most reports. The 65 to 85 age group constituted the majority of the reports. It is notable that the United States was the largest contributor of reports. The majority of HF reports occurred within 0 to 30 days after drug administration. These reports were frequently associated with serious outcomes. There were 20 drugs that met the threshold of not less than 3 reports, including bevacizumab, oxaliplatin, fluorouracil, capecitabine, and cetuximab. The Reporting Odds Ratio (ROR) method, the Proportional Reporting Ratio (PRR) method, the Bayesian Confidence Propagation Neural Network (BCPNN) method, and the Multi-item Gamma Poisson Shrinker (MGPS) method were utilized. Fluorouracil, aflibercept, ramucirumab, atezolizumab, trametinib, and ipilimumab met the criteria of more than 3 reports and a positive ROR signal. A strong association between HF risk and the utilization of aflibercept or ramucirumab in CRC was found.

Conclusion

The study offers the first real-world pharmacovigilance analysis of HF risks associated with CRC drugs using the FAERS database. It contributed critical evidence to inform the safe clinical use of CRC drugs.